QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.37 (+0.29%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.37 (+0.29%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.37 (+0.29%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.74 (-1.02%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.37 (+0.29%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.26%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Actinium Pharmaceuticals Stock Price, News & Analysis (NYSEAMERICAN:ATNM)

$4.02
-0.25 (-5.85%)
(As of 05:11 PM ET)
Compare
Today's Range
$4.00
$4.29
50-Day Range
$7.12
$14.26
52-Week Range
$4.00
$14.70
Volume
226,159 shs
Average Volume
262,238 shs
Market Capitalization
$110.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.15

Actinium Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
562.2% Upside
$27.15 Price Target
Short Interest
Healthy
6.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of Actinium Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.03) to ($1.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars


ATNM stock logo

About Actinium Pharmaceuticals Stock (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

ATNM Stock Price History

ATNM Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Actinium Pharmaceuticals to Attend Bio-Europe Munich 2023
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
See More Headlines
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/03/2023
Today
11/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ATNM
CIK
N/A
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.15
High Stock Price Target
$50.00
Low Stock Price Target
$11.60
Potential Upside/Downside
+535.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-33,020,000.00
Pretax Margin
-102,975.55%

Debt

Sales & Book Value

Annual Sales
$1.03 million
Book Value
$2.61 per share

Miscellaneous

Free Float
26,316,000
Market Cap
$117.04 million
Optionable
Not Optionable
Beta
0.31
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Sandesh C. Seth M.B.A. (Age 59)
    M.S., Chairman & CEO
    Comp: $1.15M
  • Mr. Steven O'Loughlin BS (Age 37)
    CFO & Corporate Secretary
    Comp: $585k
  • Dr. Paul Diamond Esq.
    Ph.D., Vice President of Patent & Legal Counsel
  • Dr. David Gould
    Senior Vice President of Corporate Development & Corporate Affairs
  • Dr. Bernie Cunningham P.M.P.
    Ph.D., Executive Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang
    VP & Head of Radiation Sciences
  • Dr. Avinash Desai M.D.
    Chief Medical Officer
  • Ms. Jenny Hsieh
    Chief Strategy Officer
  • Ms. Sunitha Lakshminarayanan
    Senior VP, Head of CMC & Product Development
  • Ms. Elaina Haeuber
    VP & Head of Clinical Operations














ATNM Stock Analysis - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATNM shares.
View ATNM analyst ratings
or view top-rated stocks.

What is Actinium Pharmaceuticals' stock price target for 2024?

4 brokers have issued 1-year target prices for Actinium Pharmaceuticals' shares. Their ATNM share price targets range from $11.60 to $50.00. On average, they predict the company's stock price to reach $27.15 in the next year. This suggests a possible upside of 575.4% from the stock's current price.
View analysts price targets for ATNM
or view top-rated stocks among Wall Street analysts.

How have ATNM shares performed in 2023?

Actinium Pharmaceuticals' stock was trading at $10.65 on January 1st, 2023. Since then, ATNM shares have decreased by 62.3% and is now trading at $4.02.
View the best growth stocks for 2023 here
.

Are investors shorting Actinium Pharmaceuticals?

Actinium Pharmaceuticals saw a drop in short interest in November. As of November 15th, there was short interest totaling 1,850,000 shares, a drop of 7.5% from the October 31st total of 2,000,000 shares. Based on an average daily trading volume, of 190,100 shares, the days-to-cover ratio is presently 9.7 days.
View Actinium Pharmaceuticals' Short Interest
.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its earnings results on Monday, April, 3rd. The biotechnology company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.01.

When did Actinium Pharmaceuticals' stock split?

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Brandywine Global Investment Management LLC (0.64%), Charles Schwab Investment Management Inc. (0.28%), Invesco Ltd. (0.12%), Deutsche Bank AG (0.06%), Deutsche Bank AG (0.06%) and UBS Group AG (0.04%).
View institutional ownership trends
.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:ATNM) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -